Market Place
Sourcing Support
All News #Library
BMS`s Biologics Opdivo Receive Suppl Approval in US
01 Jul 2025 //
FDA
BMS`s Biologics Yervoy Receives Suppl Approval in US
23 May 2025 //
FDA
BMS`s Biologics Opdivo Receives Suppl Approval in US
23 May 2025 //
FDA
BMS`s Biologics Opdivo Qvantig Receives Suppl Approval in US
23 May 2025 //
FDA
BMS`s Augtyro Receives Approval in Canada
07 May 2025 //
HEALTH CANADA
BMS`s Biologic Yervoy Receives Suppl Approval in US
11 Apr 2025 //
FDA
BMS`s Biologic Opdivo Receives Suppl Approval in US
11 Apr 2025 //
FDA
BMS`s Biologic Opdivo Qvantig Receives Approval in US
27 Dec 2024 //
FDA
Bristol Myers`s Biologic Opdivo (Nivolumab) Receives Suppl Approval in US
03 Oct 2024 //
FDA
BMS` Camzyos (mavacamten) Receives Approval in Europe
07 Aug 2023 //
EMA
Bristol Myers Squibb`s Camzyos (mavacamten) Receives Approval in Europe
24 Jul 2023 //
EMA
Bristol`s Biologic Yervoy (Ipilimumab) Receives Approval in the U.S.
23 Nov 2022 //
FDA
Bristol`s Opdualag (Nivolumab, Relatlimab) Receives Approval in Europe
20 Sep 2022 //
EMA
Bristol Myers Squibb`s Opdivo (nivolumab)
14 Jul 2022 //
FDA
BMS Breyanzi (lisocabtagene maraleucel) Receives Approval in Europe
20 May 2022 //
EMA
Bristol Myers Biologic Yervoy (Ipilimumab) Receives Approval in the U.S.
11 May 2022 //
FDA
Bristol Myers Biologic Opdivo(Nivolumab) Receives Approval in the U.S.
11 May 2022 //
FDA
Bristol Myers` Biologic Orencia (Abtacept) Receives Approval in the U.S.
13 Apr 2022 //
FDA
BMS` Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.
22 Mar 2022 //
FDA
Bristol Myers Squibb`s Biologic Opdivo (Nivolumab) Receives Approval in U.S.
04 Mar 2022 //
FDA
Bristol Myers Squibb`s Biologic Opdivo (Nivolumab) Receives Approval in U.S.
25 Feb 2022 //
FDA
BMS`s Biological Nivolumab Receives Supplemental Approval In the US
20 Aug 2021 //
FDA
Bristol Myers Squibb`s Biological Nivolumab Receives Approval in the USA
15 Jul 2021 //
FDA
Bristol Myers Squibb`s Biological Nivolumab Receives Approval In US
06 Oct 2020 //
FDA
Bristol Myers Squibb`s Biological Ipilimumab Receives Approval In US
06 Oct 2020 //
FDA
Bristol Myers Squibb`s Biological Nivolumab Receives Approval In US
22 Sep 2020 //
FDA
Bristol Myers Squibb`s Biological Ipilimumab Receives Approval In US
22 Sep 2020 //
FDA
Bristol Myers`s Orencia (Abatacept ) Receives Supplemental Approval in US
24 Jun 2020 //
FDA
Bristol Myers`s Opidivo (Nivolumab ) Receives Supplemental Approval in US
16 Jun 2020 //
FDA
Bristol Myers`s Yervoy (Ipilimumab ) Receives Supplemental Approval in US
12 Mar 2020 //
FDA
Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US
31 Oct 2019 //
FDA
Bristol Myers Yervoy (Ipilimumab) Receives Supplemental Approval in US
24 Sep 2019 //
FDA
Bristol Myers Opdivo (Nivolumab) Receives Supplemental Approval in US
20 Sep 2019 //
FDA
Bristol Myers Squibb’s Nivolumab Receives Supplemental Approval In US
08 Sep 2017 //
FDA
Bristol Myers Squibb’s Opdivo Nivolumab Receives Supplemental Approval In US
02 Aug 2017 //
FDA
Bristol Myers Squibb Opdivo Nivolumab Receives Supplemental Approval In US
26 Apr 2017 //
FDA
Bristol Myers Squibb`s Supplement Opdivo (Nivolumab) Receives Approval In US
02 Feb 2017 //
FDA
Bristol`s Supplementary Opdivo Receives Approval In US
10 Nov 2016 //
FDA
Bristol`s Nivolumab Approved in US
13 Sep 2016 //
FDA
BMS`s Empliciti receives marketing authorisatiom in EU for Multiple Myeloma
19 May 2016 //
EMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.